These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18808314)

  • 1. Ertumaxomab: a trifunctional antibody for breast cancer treatment.
    Kiewe P; Thiel E
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1553-8. PubMed ID: 18808314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
    Jäger M; Schoberth A; Ruf P; Hess J; Lindhofer H
    Cancer Res; 2009 May; 69(10):4270-6. PubMed ID: 19435924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
    Kiewe P; Hasmüller S; Kahlert S; Heinrigs M; Rack B; Marmé A; Korfel A; Jäger M; Lindhofer H; Sommer H; Thiel E; Untch M
    Clin Cancer Res; 2006 May; 12(10):3085-91. PubMed ID: 16707606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling.
    Diermeier-Daucher S; Ortmann O; Buchholz S; Brockhoff G
    MAbs; 2012; 4(5):614-22. PubMed ID: 22820509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
    Haense N; Atmaca A; Pauligk C; Steinmetz K; Marmé F; Haag GM; Rieger M; Ottmann OG; Ruf P; Lindhofer H; Al-Batran SE
    BMC Cancer; 2016 Jul; 16():420. PubMed ID: 27387446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
    Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
    J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p95HER2-T cell bispecific antibody for breast cancer treatment.
    Rius Ruiz I; Vicario R; Morancho B; Morales CB; Arenas EJ; Herter S; Freimoser-Grundschober A; Somandin J; Sam J; Ast O; Barriocanal ÁM; Luque A; Escorihuela M; Varela I; Cuartas I; Nuciforo P; Fasani R; Peg V; Rubio I; Cortés J; Serra V; Escriva-de-Romani S; Sperinde J; Chenna A; Huang W; Winslow J; Albanell J; Seoane J; Scaltriti M; Baselga J; Tabernero J; Umana P; Bacac M; Saura C; Klein C; Arribas J
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
    Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
    J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.
    Cai Z; Zhang G; Zhou Z; Bembas K; Drebin JA; Greene MI; Zhang H
    Oncogene; 2008 Jun; 27(27):3870-4. PubMed ID: 18264138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
    Shalaby MR; Carter P; Maneval D; Giltinan D; Kotts C
    Clin Immunol Immunopathol; 1995 Feb; 74(2):185-92. PubMed ID: 7828373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.